CMG Pharmaceutical Applies for FDA Approval of World's First Film-Type Schizophrenia Treatment
[Asia Economy Reporter Cho Hyun-ui] CMG Pharmaceutical announced on the 2nd that it has applied for approval of the film-type schizophrenia treatment 'Depipjo' from the U.S. Food and Drug Administration (FDA).
Depipjo is the world's first film-type schizophrenia treatment. By applying technology developed in-house, CMG Pharmaceutical minimized film damage and deterioration and effectively blocked the bitter taste of the medicine, improving portability and ease of administration.
Mental illness patients often refuse medication when symptoms worsen. The film formulation can be taken without water and dissolves easily in the mouth, which is expected to reduce such problems.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
CMG Pharmaceutical plans to sell the product in the U.S. as early as the second half of this year after FDA approval review. CMG Pharmaceutical CEO Lee Joo-hyung said, "If Depipjo receives marketing approval, we are selecting local partners in the U.S. to start sales immediately," adding, "We plan to expand the market to various regions including Europe besides the U.S."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
